Experts predict that by 2035, the global obesity prevalence rate is expected to rise to 24%, affecting the lives of nearly 2 billion people. Obesity has many complications, such as type 2 diabetes, chronic kidney disease, etc.

    Tirzepatide is a double agonist of glucose dependent insulin stimulating polypeptide (GIP) and Glucagon like peptide 1 (GLP-1) receptors. It is administered subcutaneously once a week to treat adult type 2 diabetes. It has been confirmed that tirzepatide is effective and safe in weight loss of overweight/obese type 2 diabetes patients.